Which of the following statements is correct?
Sclerostin is produced mainly by the osteoblast precursors
Sclerostin stimulates the Wnt signalling pathway
Sclerostin activates the lining cells
A mutation in the sclerostin gene is the cause of Van Buchem Disease
Glucocorticoids inhibit sclerostin formation
Romosozumab induces a rapid increase in bone formation and inhibition of bone resorption
Romosozumab is recommended as a treatment for premenopausal women at risk of fracture
Romosozumab has not been shown to have anti-fracture efficacy in non-vertebral fractures
Romosozumab stimulates bone formation primarily by stimulating modelling-based formation on the periosteal surfaces
There is no need to initiate further therapy after stopping romosozumab
Romosozumab is a polyclonal antibody inhibiting sclerostin
Romosozumab reduces the risk of fracture risk only at the spine
Greater BMD increases are achieved when romosozumab is given before, rather than after, an antiresorptive agent
No cardiac risks have been documented with romosozumab
Romosozumab has a similar amplitude of effect on BMD compared to other anabolic agents
What is the recommended duration of romosozumab therapy?
6 months
12 months
24 months
5 years
Lifetime use is recommended
What is the main safety concern associated with romosozumab?
Severe renal impairment
Increased risk of cardiovascular events
Serious gastrointestinal side effects requiring hospitalisation
Leg cramps
Risk of severe hypercalcaemia